Incidence of catheter-related thrombosis in patients with long-term indwelling central venous catheter who received chemotherapies for unresectable...

Date 24 November 2018
Event ESMO Asia 2018 Congress
Session Poster display - Cocktail
Topics Supportive Measures
Complications/Toxicities of Treatment
Gastrointestinal Cancers
Presenter Hiroaki Tanioka
Citation Annals of Oncology (2018) 29 (suppl_9): ix46-ix66. 10.1093/annonc/mdy432
Authors H. Tanioka1, M. Asano2, K. Kawasaki3, R. Yoshida3, N. Waki4, F. Uno4, M. Ishizaki4, K. Yamashita4, Y. Morishita5, Y. Katata1, T. Nagasaka6
  • 1Medical Oncology, Kawasaki Medical School Hospital, 701-0192 - Kurashiki/JP
  • 2Internal Medicine, Okayama Rosai Hospital, Okayama/JP
  • 3Surgery, Okayama Rosai Hospital, Okayama/JP
  • 4Surgery, Okayama Rosai Hospital, 7028055 - Okayama/JP
  • 5Pharmaceutical Department, Okayama Rosai Hospital, 7028055 - Okayama/JP
  • 6Medical Oncology, Kawasaki Medical School Hospital, 701-0192 - Kurasiki-city/JP



Most of patients with unresectable advanced digestive cancers requires placement of a totally implantable venous access port to facilitate safe delivery of anti-cancer drugs. Among digestive cancers, such as gastric and colorectal cancers, anti-VEGF therapies are commonly used even so increasing the risk of thrombosis. The objective of this study was to assess the incidence of radiologically confirmed catheter-related thrombosis in patients with advanced digestive cancers and to determine the risk factors of thrombosis.


We retrospectively reviewed the medical records of 109 patients with advanced digestive cancers who adapted implantable ports placed in our institution for chemotherapy between January 2015, and December 2016.


Of 109 patients, 88 patients had been evaluated with enhanced-CT continuously. Thirty-nine patients were diagnosed as colorectal cancer, 26 as gastric, 12 as pancreatic, 8 as esophageal, and 3 as other cancers, respectively. There were 25 women and 63 men, with a mean age of 70 years old (range: 44 to 89). The median follow-up time after the index port placement was 488 days (range: 21-1037). During follow-up, 22 patients (25%) received anti-VEGF therapies, while 66 patients did not receive anti-VEGF therapies (75%). Four patients of 88 patients (4.5%) had catheter-related thrombosis asymptomatically. The median time to first catheter-related thrombosis development was 260.5 days (range: 44 to 450). Two patients (7.7%) with thrombosis were gastric cancer, one patient (2.6%) was colorectal cancer and one was pancreatic gastrinoma (p = 0.56). Among the four patients developed the catheter-related thrombosis, one patients with gastric cancer was received anti-VEGF therapy (4.5% [1/22] of patients who received anti-VEGF therapies) and three patients was not treated by ant-VEGF therapies (4.5% [3/66] of patients who received no anti-VEGF therapy, p = 1.0).


In patients with digestive cancers who had implantable venous access port, incidence of the catheter-related thrombosis was 4.5% and there is no association to anti-VEGF therapies.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Hiroaki Tanioka.


Has not received any funding.


All authors have declared no conflicts of interest.